Cargando…

Durability of Protection Post–Primary COVID-19 Vaccination in the United States

The durability of immune responses after COVID-19 vaccination will drive long-term vaccine effectiveness across settings and may differ by vaccine type. To determine durability of protection of COVID-19 vaccines (BNT162b2, mRNA-1273, and Ad26.COV2.S) following primary vaccination in the United State...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheutlin, Amanda, Ott, Miles, Sun, Ran, Zemlianskaia, Natalia, Meyer, Craig S., Rubel, Meagan, Hayden, Jennifer, Neri, Breno, Kamath, Tripthi, Khan, Najat, Schneeweiss, Sebastian, Sarsour, Khaled
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505933/
https://www.ncbi.nlm.nih.gov/pubmed/36146536
http://dx.doi.org/10.3390/vaccines10091458
_version_ 1784796596953677824
author Zheutlin, Amanda
Ott, Miles
Sun, Ran
Zemlianskaia, Natalia
Meyer, Craig S.
Rubel, Meagan
Hayden, Jennifer
Neri, Breno
Kamath, Tripthi
Khan, Najat
Schneeweiss, Sebastian
Sarsour, Khaled
author_facet Zheutlin, Amanda
Ott, Miles
Sun, Ran
Zemlianskaia, Natalia
Meyer, Craig S.
Rubel, Meagan
Hayden, Jennifer
Neri, Breno
Kamath, Tripthi
Khan, Najat
Schneeweiss, Sebastian
Sarsour, Khaled
author_sort Zheutlin, Amanda
collection PubMed
description The durability of immune responses after COVID-19 vaccination will drive long-term vaccine effectiveness across settings and may differ by vaccine type. To determine durability of protection of COVID-19 vaccines (BNT162b2, mRNA-1273, and Ad26.COV2.S) following primary vaccination in the United States, a matched case-control study was conducted in three cohorts between 1 January and 7 September 2021 using de-identified data from a database covering 168 million lives. Odds ratios (ORs) for developing outcomes of interest (breakthrough SARS-CoV-2 infection, hospitalization, or intensive care unit admission) were determined for each vaccine (no direct comparisons). In total, 17,017,435 individuals were identified. Relative to the baseline, stable protection was observed for Ad26.COV2.S against infections (OR [95% confidence interval (CI)], 1.31 [1.18–1.47]) and hospitalizations (OR [95% CI], 1.25 [0.86–1.80]). Relative to the baseline, protection waned over time against infections for BNT162b2 (OR [95% CI], 2.20 [2.01–2.40]) and mRNA-1273 (OR [95% CI], 2.07 [1.87–2.29]) and against hospitalizations for BNT162b2 (OR [95% CI], 2.38 [1.79–3.17]). Baseline protection remained stable for intensive care unit admissions for all three vaccines. Calculated baseline VE was consistent with published literature. This study suggests that the three vaccines in three separate populations may have different durability profiles.
format Online
Article
Text
id pubmed-9505933
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95059332022-09-24 Durability of Protection Post–Primary COVID-19 Vaccination in the United States Zheutlin, Amanda Ott, Miles Sun, Ran Zemlianskaia, Natalia Meyer, Craig S. Rubel, Meagan Hayden, Jennifer Neri, Breno Kamath, Tripthi Khan, Najat Schneeweiss, Sebastian Sarsour, Khaled Vaccines (Basel) Article The durability of immune responses after COVID-19 vaccination will drive long-term vaccine effectiveness across settings and may differ by vaccine type. To determine durability of protection of COVID-19 vaccines (BNT162b2, mRNA-1273, and Ad26.COV2.S) following primary vaccination in the United States, a matched case-control study was conducted in three cohorts between 1 January and 7 September 2021 using de-identified data from a database covering 168 million lives. Odds ratios (ORs) for developing outcomes of interest (breakthrough SARS-CoV-2 infection, hospitalization, or intensive care unit admission) were determined for each vaccine (no direct comparisons). In total, 17,017,435 individuals were identified. Relative to the baseline, stable protection was observed for Ad26.COV2.S against infections (OR [95% confidence interval (CI)], 1.31 [1.18–1.47]) and hospitalizations (OR [95% CI], 1.25 [0.86–1.80]). Relative to the baseline, protection waned over time against infections for BNT162b2 (OR [95% CI], 2.20 [2.01–2.40]) and mRNA-1273 (OR [95% CI], 2.07 [1.87–2.29]) and against hospitalizations for BNT162b2 (OR [95% CI], 2.38 [1.79–3.17]). Baseline protection remained stable for intensive care unit admissions for all three vaccines. Calculated baseline VE was consistent with published literature. This study suggests that the three vaccines in three separate populations may have different durability profiles. MDPI 2022-09-03 /pmc/articles/PMC9505933/ /pubmed/36146536 http://dx.doi.org/10.3390/vaccines10091458 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zheutlin, Amanda
Ott, Miles
Sun, Ran
Zemlianskaia, Natalia
Meyer, Craig S.
Rubel, Meagan
Hayden, Jennifer
Neri, Breno
Kamath, Tripthi
Khan, Najat
Schneeweiss, Sebastian
Sarsour, Khaled
Durability of Protection Post–Primary COVID-19 Vaccination in the United States
title Durability of Protection Post–Primary COVID-19 Vaccination in the United States
title_full Durability of Protection Post–Primary COVID-19 Vaccination in the United States
title_fullStr Durability of Protection Post–Primary COVID-19 Vaccination in the United States
title_full_unstemmed Durability of Protection Post–Primary COVID-19 Vaccination in the United States
title_short Durability of Protection Post–Primary COVID-19 Vaccination in the United States
title_sort durability of protection post–primary covid-19 vaccination in the united states
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505933/
https://www.ncbi.nlm.nih.gov/pubmed/36146536
http://dx.doi.org/10.3390/vaccines10091458
work_keys_str_mv AT zheutlinamanda durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates
AT ottmiles durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates
AT sunran durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates
AT zemlianskaianatalia durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates
AT meyercraigs durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates
AT rubelmeagan durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates
AT haydenjennifer durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates
AT neribreno durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates
AT kamathtripthi durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates
AT khannajat durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates
AT schneeweisssebastian durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates
AT sarsourkhaled durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates